- Home
- TLPH vs INMB Comparison
TLPH vs INMB Comparison
Compare TLPH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.74
HOLD
Current Price
$1.15
Company Overview
Basic Information| Metric | TLPH | INMB |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 34.3M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TLPH | INMB |
|---|---|---|
| Price | $0.74 | $1.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $5.87 |
| AVG Volume (30 Days) | 203.9K | ★ 430.7K |
| Earning Date | 03-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $14,000.00 |
| Revenue This Year | N/A | $264.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $1.12 |
| 52 Week High | $1.57 | $11.64 |
Technical Indicators
Market Signals| Indicator | TLPH | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 36.74 |
| Support Level | $0.40 | N/A |
| Resistance Level | $0.79 | $1.48 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.07 | 1.56 |
Price Performance
Historical Comparison TLPH
INMB
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.